Marinomed Biotech AG
WKN: A2N9MM | ISIN: ATMARINOMED6 | FSE: 93Z | VIE: MARI
Marinomed Biotech AG focuses on innovative pharmaceuticals for the treatment of immunological and inflammatory diseases. Following a comprehensive restructuring in 2024, including the sale of its Carragelose® business to Unither Pharmaceuticals, the company is now fully dedicated to its patented Marinosolv® technology platform.
Technology in Focus: Marinosolv®
Marinosolv® is an innovative technology designed to improve the solubility and bioavailability of poorly soluble active ingredients, particularly for use in the treatment of immunological and inflammatory conditions.
The current development pipeline centers around two key products:
Budesolv: A low-dose corticosteroid nasal spray for the treatment of allergic rhinitis (“seasonal allergies”), offering fast onset of action and a preservative-free formulation.
Tacrosolv: An innovative eye drop formulation of the immunomodulator tacrolimus for the treatment of inflammatory eye diseases.
The pipeline is further complemented by Solv4U, a growing business segment that provides pharmaceutical companies with access to the Marinosolv® technology for the development of their own drug formulations.